{
    "nctId": "NCT00673829",
    "briefTitle": "Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer",
    "officialTitle": "Phase Ia/Ib Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer",
    "overallStatus": "SUSPENDED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 26,
    "primaryOutcomeMeasure": "Phase Ia:Determine the safety of using modified T-cells by documenting the type and severity of any side effects and establishing the maximum tolerated dose (MTD).",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Must have cancer of the breast\n* Must have metastatic or unresectable locally advanced disease\n* Tumor must express CEA by tumor staining or by elevated serum CEA (\\>10 ng/ml)\n* Must have measurable disease radiologically or by physical exam\n* Must have failed potentially curative standard therapy\n* Must be 18 years of age or older\n* Good performance status (PS 0-1)\n\nExclusion Criteria:\n\n* Requiring systemic steroids\n* Serious medical conditions\n* Concurrent malignancies",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}